Stockholm, Sweden - March 14, 2017 - ContextVision, a leading provider of medical imaging software specializing in image analysis and artificial intelligence, received a patent approval on a new technology for the visualization of the skeleton from 3D ultrasound. The patent was filed in 2014.
The technology is based on a visualization software and improves the potential for early discovery of skeletal irregularities in unborn babies.
This offers a unique product feature named SkeletalView which is integrated into ContextVision's groundbreaking 3D rendering product, REALiCE, which is commercially available.
SkeletalView enables the clinicians to obtain a more accurate view of the fetal skeleton during pregnancy. This product feature helps the clinicians examine the fetus for spontaneous fractures and skeletal malformations. It also facilitates the measurement of bone structures.
"Our new visualization product REALiCE has received significant industry attention since it was launched. SkeletalView adds diagnostic value, and makes the product even more attractive to manufacturers of medical imaging equipment," said ContextVision's CEO, Anita Tollstadius.
For further information, please contact ContextVision's CEO, Anita Tollstadius, at +46 70 337 30 26.
ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision is taking a leading position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing significantly in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit http://www.contextvision.com.